相关实验视频

Updated: Jul 25, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

在高级非小细胞肺癌中,每6周服用布罗利祖马布,而每3周服用布罗利祖马布

Maude Dubé-Pelletier¹, Catherine Labbé¹, Jimmy Côté¹

¹Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, Canada.

|June 26, 2023

概括

与每3周一次 (Q3W) 治疗方案相比,每6周一次 (Q6W) 布洛利祖马布的整体存活率,无进展存活率和毒性与晚期非小细胞肺癌 (NSCLC) 患者相似.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

布罗利祖马布是高级非小细胞肺癌 (NSCLC) 的关键免疫疗法.
已确定的剂量包括每3周 (Q3W) 服用2mg/kg.
另一个4mg/kg每6周 (Q6W) 方案被批准,但缺乏NSCLC的直接比较数据.

研究的目的:

直接比较pembrolizumab Q6W与Q3W在高级NSCLC中的疗效和安全性.
评估总生存 (OS) 和无进展生存 (PFS) 的差异.
评估免疫媒介不良事件 (AE) 的发生和严重程度.

主要方法:

在IUCPQ对160名晚期NSCLC患者的回顾性分析.
80名患者接受了潘布罗利祖马布4毫克/公斤Q6W; 80名患者接受了2毫克/公斤Q3W.
主要结局:OS,PFS和等级≥3的免疫媒介性AE. 数据截止日期:2022年12月15日.

主要成果:

平均PFS:6.9个月 (Q6W) 与8.9个月 (Q3W) (aHR为1.27,P=.25) 相比.
中位 OS:未达到 (Q6W) 与20.5个月 (Q3W) (aHR 0.80,P=.36) 相比.
免疫介导的AEs等级≥3:18% (Q6W) 与19% (Q3W) 相比.

结论:

潘布罗利祖马布Q6W剂量方案与晚期NSCLC中的Q3W方案相似.
两种剂量表之间没有观察到OS,PFS或毒性的显著差异.
这项回顾性研究支持Q6W疗法作为先进NSCLC治疗的可行替代方案.

关键词:

晚期非小细胞肺癌晚期非小细胞肺癌潘布罗利祖马布2毫克/公斤每3周一次.潘布罗利祖马布4毫克/公斤每6周一次

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Drug Dosage Regimen: Overview

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...